GlassScriptPhysician profile
Jordan Spencer
NPI 1851886782
$61,885.31
in general payments reported to CMS, 2019-2025
28 companies · $58K in 2025
The $58K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2023: $857 · 2024: $2,960 · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $46K · Food and Beverage: $8,325 · Travel and Lodging: $3,428 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,550 · Consulting Fee: $1,000 · Education: $4.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $46,475.00 |
| Food and Beverage | $8,324.81 |
| Travel and Lodging | $3,427.82 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,550.00 |
| Consulting Fee | $1,000.00 |
| Education | $4.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $51,322.34 | 2023-2025 | Auvelity, Symbravo, Sunosi |
| Alkermes, INC. | $4,150.80 | 2023-2025 | Vivitrol, Aristada, Lybalvi |
| Abbvie INC. | $1,325.22 | 2023-2025 | Vraylar, Qulipta, Ubrelvy |
| Vanda Pharmaceuticals INC. | $922.39 | 2023-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $590.24 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $407.14 | 2023-2025 | Spravato |
| Lundbeck LLC | $377.35 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $363.22 | 2023-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Neos Therapeutics, LP | $244.87 | 2023-2025 | Adzenys Xr-Odt |
| Neurocrine Biosciences, INC. | $238.72 | 2023-2025 | Ingrezza |
| Janssen Scientific Affairs, LLC | $200.00 | 2025 | Spravato |
| Indivior INC. | $175.32 | 2023-2025 | Sublocade |
| Bausch Health US, LLC | $171.69 | 2023-2025 | Aplenzin |
| Harmony Biosciences LLC | $151.41 | 2023-2025 | Wakix |
| Noven Therapeutics, LLC | $149.26 | 2024-2025 | Xelstrym, Secuado |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $148.77 | 2023-2025 | Quviviq, Quviviq |
| Teva Pharmaceuticals USA, INC. | $144.65 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Corium, LLC | $121.74 | 2023-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $110.16 | 2024-2025 | Cobenfy |
| Tris Pharma INC | $106.09 | 2024-2025 | Dyanavel Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $102.95 | 2019 | |
| Almatica Pharma LLC | $89.31 | 2024-2025 | Loreev Xr |
| Pfizer INC. | $85.59 | 2025 | |
| Braeburn INC. | $63.49 | 2024-2025 | Brixadi |
| Collegium Pharmaceutical, INC. | $46.78 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $36.54 | 2024-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $21.76 | 2023 | Belsomra |
| Ironshore Pharmaceuticals INC. | $17.51 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.